David Dominguez-Sola, MD, PhD

MYC-dependent replication stress as a pathogenic driver and therapeutic target in aggressive B cell lymphomas

B cell lymphomas with MYC gene alterations are very aggressive and not curable using current therapies. Targeting MYC would thus be an ideal therapeutic strategy in these patients. Here, we describe a cellular process representing a unique vulnerability in MYC-driven lymphomas and propose to determine its therapeutic value.